How THC, CBD, and the Endocannabinoid System Actually Work

The Technical Framework

• CB1 Receptors: Concentrated heavily in the Central Nervous System (CNS). They function as a brake on the release of glutamate and GABA.
• CB2 Receptors: Found primarily in the Peripheral Nervous System (PNS) and immune-dense tissues. They manage cytokine signaling and the systemic inflammatory response.
• Ligand Binding: THC and CBD operate as exogenous ligands. They originate outside the body but modulate these internal receptor sites to alter physiological states.
• Enzymatic Degradation: Enzymes like Fatty Acid Amide Hydrolase (FAAH) and Monoacylglycerol Lipase (MAGL) act as the cleanup crew, breaking down cannabinoids. Inhibiting these enzymes may extend the half-life of your body's own cannabinoids.

The ECS: Maintaining Biological Balance

Every vertebrate relies on the ECS to keep internal variables within an optimal range. When a system drifts—such as during an acute immune flare-up or excessive neuronal firing—the body synthesizes endocannabinoids "on demand."

Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) are the primary players here. They utilize retrograde signaling. While standard neurotransmission moves from the presynaptic to the postsynaptic neuron, endocannabinoids travel in reverse. They head from the receiving neuron back to the sender to signal a reduction in chemical output, acting as a biological circuit breaker.

THC: CB1 Receptor Agonism and Signal Transduction

Delta-9-Tetrahydrocannabinol (THC) is a partial agonist of the CB1 receptor. Its molecular structure is a near-match for Anandamide, allowing it to lock into the receptor site.

Because THC has a higher binding affinity and a slower degradation rate than internal molecules, it exerts a sustained effect. In the basal ganglia, this may disrupt motor control; in the hippocampus, it may interfere with short-term memory encoding.

What happens when THC binds:

• G-Protein Activation: Triggers an intracellular signaling cascade that alters neuronal behavior.
• Dopamine Modulation: By inhibiting GABA (the primary "calming" neurotransmitter) in the ventral tegmental area, THC may indirectly influence dopamine levels.
• Analgesia: Activation of CB1 receptors in the spinal cord and periaqueductal gray may dampen ascending pain signals.

CBD: Non-Competitive Antagonism and Allosteric Modulation

Cannabidiol (CBD) is distinct because it does not bind to the main active sites of CB1 or CB2. Instead, it functions as a Negative Allosteric Modulator (NAM).

CBD binds to a secondary site on the receptor, physically shifting its shape. This conformational change makes it harder for THC to dock, which is why CBD may act as a buffer against THC-induced tachycardia and paranoia.

FAAH Inhibition

CBD may boost natural "bliss molecules" by inhibiting the FAAH enzyme. By slowing the breakdown of Anandamide, CBD keeps these endogenous compounds circulating longer, which may support anxiolytic effects without the effects associated with direct receptor stimulation.

Secondary Pathways

CBD interacts with several systems outside the standard ECS:

• 5-HT1A Serotonin Receptors: CBD acts as a direct agonist here, which may support anxiety and mood regulation.
• TRPV1 (Vanilloid) Receptors: These manage pain and inflammation. CBD may desensitize these receptors, potentially turning down the volume on pain sensors.
• GPR55: Often called the "orphan receptor," it plays a role in bone density and vascular pressure. CBD acts as an antagonist here, which may influence bone reabsorption.

The Entourage Effect: Synergistic Interaction

Cannabinoids often work in concert with other compounds. The presence of terpenes—the aromatic compounds in the plant—may alter how these molecules are absorbed and processed.

Beta-Caryophyllene acts as a selective CB2 agonist. When paired with CBD, it may support anti-inflammatory responses. Myrcene is thought to increase the permeability of the blood-brain barrier, potentially acting as a facilitator for THC to reach CB1 receptors.

Using a 1:1 THC to CBD ratio is a common strategy to balance these effects. CBD occupies the allosteric sites to prevent THC from over-stimulating the CNS, while both compounds may address inflammation through CB2 and TRPV1 pathways.

Practical Application: Selecting the Right Ratio

Targeted therapy involves matching the chemical profile to the intended physiological outcome:

1. Inflammation: High-CBD profiles (20:1) maximize FAAH inhibition and CB2 activation without the cognitive impairment of THC.
2. Neuropathic Pain: A 1:1 or 2:1 (CBD:THC) ratio is often utilized. The THC supports central analgesia, while the CBD modulates the psychoactive ceiling.
3. Sleep Architecture: While high-THC doses may decrease the time it takes to fall asleep, they can reduce REM sleep. Incorporating Cannabinol (CBN)—a degradation product of THC—is often preferred, as it favors CB2 activation and may support sedative effects.
4. Anxiety Management: CBD-dominant chemotypes that prioritize 5-HT1A activation are often preferred. High-THC concentrations may exacerbate fight-or-flight responses in some individuals.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Devane WA, Hanus L, Breuer A, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258(5090):1946-49. PubMed

2. Mechoulam R, Ben-Shabat S, Hanus L, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50(1):83-90. PubMed

3. Pertwee RG. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 153(2):199-215. PubMed

4. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

5. Pacher P, Bátkai S, Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58(3):389-462. PubMed